Narcolepsy is a medical condition which is characterized by overwhelming daytime drowsiness and sudden attacks of sleep. Sometimes, this chronic sleep disorder can lead to a sudden loss of muscle tone (cataplexy), leading to weakness and loss of muscle control. Sleep paralysis, hallucinations, daytime sleepiness, fragmented sleep & insomnia, besides others are some of the most common symptoms of the disease.
Increasing prevalence of narcolepsy, growing the obese population, increasing demands for effective treatment, rising research and development are estimated to be some of the significant drivers for the Global narcolepsy market. However, lack of awareness and low per capita healthcare expenditure in the middle and low-income countries may restraint the Global narcolepsy market growth, during the forecast period. Global Narcolepsy Market is expected to grow at an approximate CAGR of 8.2% during the forecast period.
Global Narcolepsy Market Share report gives expected growth of Top players at CAGR 8.2% during the forecast period of 2018-2023. Market is segmented on the basis of type, diagnosis, treatment, and end user.
Key Players for Global Narcolepsy Market
Jazz Pharmaceuticals plc (Republic of Ireland), BIOPROJET (Paris), Arena Pharmaceuticals, Inc. (U.S.), Graymark Healthcare, Inc. (U.S.), Mylan N.V. (U.S., Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Shire (Republic of Ireland), Shionogi Inc. (U.S.), Ligand Pharmaceuticals, Inc. (U.S.), and others
Regional Analysis for Global Narcolepsy Market
America dominates the Global narcolepsy market owing to a well-developed healthcare sector, high healthcare expenditure and a huge patient population. According to the National Institute of Neurological Disorders and Stroke in 2018, it is estimated that approximately 135,000 to 200,000 people in the United States are living with narcolepsy.
Europe is the second largest market for narcolepsy and is followed by Asia Pacific owing to the availability of funds for research, huge patient population, growing number of obese, and presence of developed economies like France, Italy, and Germany within the region
Asia Pacific is estimated to be the fastest growing region for the Global narcolepsy market. Presence of developing economies like India and China within the region and developing healthcare sector facilitates the regional market growth
The Middle East & Africa has the least share in the Global narcolepsy market. Factors such as the presence of weak economies and stringent government policies especially within in the African region makes the market to lag within the region.
Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/narcolepsy-market-5701
Segments for Global Narcolepsy Market
Global Narcolepsy Market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the market is segmented into type 1 narcolepsy, type 2 narcolepsy, and others, on the basis of the diagnosis, the market is categorized into polysomnogram, multiple sleep latency test, others. On the basis of the treatment, the market is segmented into stimulants, antidepressants, sodium oxybate, and others and on the basis of the end users, the market is segmented into hospitals, clinics, retail pharmacies, and others.
Related News
Acute Coronary Syndrome Market
Sex Cord Gonadal Stromal Tumor Market
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Global Narcolepsy Market Research Report, By Type (Type 1, Type 2 Narcolepsy) Diagnosis (Polysomnogram, Multiple Sleep Latency Test) Treatment (Stimulants, Antidepressants, Sodium Oxybate) End Users (Hospitals, Retail Pharmacies) – Global Forecast Till 2023Market Highlights:Increasing prevalence of narcolepsy, growing the obese population, increasing demands for effective treatment, rising research and development are estimated to be some of the significant drivers for the global narcolepsy market.
However, lack of awareness and low per capita healthcare expenditure in the middle and low-income countries may restraint the global narcolepsy market growth, during the forecast period.Intended AudiencePharmaceutical companiesBiotechnological institutesResearch and Development (R) CompaniesMedical Research LaboratoriesMarket Research and Consulting Service ProvidersAvail a Free Sample@ https://www.marketresearchfuture.com/sample_request/5701SegmentationThe Global Narcolepsy Market is segmented on the basis of type, diagnosis, treatment, and end user.By the type, the market is segmented into type 1 narcolepsy, type 2 narcolepsy, and others.On the basis of the diagnosis, the market is categorized into polysomnogram, multiple sleep latency test, others.
The stimulants segment is sub-segmented into modafinil, armodafinil, and others.
This can be attributed due to the presence of well-developed healthcare sector, high healthcare expenditure and huge patient population.
Moreover, the presence of developed economies like U.S. and Canada and global players such as Mylan N.V., Ligand Pharmaceuticals, Inc., and others within the region fuels the market growth.
Europe is the estimated to stand second in the global narcolepsy market owing to the availability of funds for research, huge patient population, growing number of obese, and presence of developed economies like France, Italy, and Germany within the region.
Market HighlightsIncreasing prevalence of pulmonary edema and diseases like kidney failure, heart diseases, and others along with the growing geriatric population boosts the market growth.
On the other hand, low per capita healthcare expenditure in the middle and low-income countries, and lack of awareness about the disease are estimated to restrain the market growth.The global pulmonary edema market is expected to grow at an approximate CAGR of 7.2% during the forecast period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5607SegmentationThe global pulmonary edema market is segmented on the basis of type, diagnosis, treatment, and end user.
The blood tests segment is sub-segmented into b-type natriuretic peptide (BNP), blood count test, kidney function test, and others.
On the basis of the treatment, the market is segmented into preload reducers, morphine, suction catheter, and others.
The preload reducers segment is sub-segmented into nitroglycerin, diuretics, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, retail pharmacies, and others.Regional AnalysisAmerica dominates the global pulmonary edema market due to the presence of a well-developed healthcare sector, high per capita healthcare expenditure and developed economies such as the U.S. and Canada within the region.
Global Narcolepsy Market Research Report, By Type (Type 1, Type 2 Narcolepsy) Diagnosis (Poysomnogram, Multiple Sleep Latency Test) Treatment (Stimulants, Antidepressants, Sodium Oxybate) End Users (Hospitals, Retail Pharmacies) – Global Forecast Till 2027Market HighlightsIncreasing prevalence of narcolepsy, growing the obese population, increasing demands for effective treatment, rising research and development are estimated to be some of the significant drivers for the global narcolepsy market.
However, lack of awareness and low per capita healthcare expenditure in the middle and low-income countries may restraint the global narcolepsy market growth, during the forecast period.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5701SegmentationThe Global Narcolepsy Market is segmented on the basis of type, diagnosis, treatment, and end user.By the type, the market is segmented into type 1 narcolepsy, type 2 narcolepsy, and others.On the basis of the diagnosis, the market is categorized into polysomnogram, multiple sleep latency test, others.
The stimulants segment is sub-segmented into modafinil, armodafinil, and others.
This can be attributed due to the presence of well-developed healthcare sector, high healthcare expenditure and huge patient population.
Moreover, the presence of developed economies like U.S. and Canada and global players such as Mylan N.V., Ligand Pharmaceuticals, Inc., and others within the region fuels the market growth.
Europe is the estimated to stand second in the global narcolepsy market owing to the availability of funds for research, huge patient population, growing number of obese, and presence of developed economies like France, Italy, and Germany within the region.
The Anterior Uveitis Treatment Market report additionally states import/trade utilization, free market activity figures, cost, value, volume and gross edges.
Global anterior uveitis treatment market is set to witness a substantial CAGR of 5.55% in the forecast period of 2019- 2026.
The report contains data of the base year 2018 and historic year 2017Get Sample Analysis of This Market Information: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-anterior-uveitis-treatment-marketMarket Definition: Global Anterior Uveitis Treatment MarketAnterior uveitis is a condition which causes inflammation in the middle layer of the eyes.
This disease can cause glaucoma, retinal edema and cataract which can further damage the eyes permanent and vision loss as well.
Some of the common symptoms of this condition are red & sore eyes, blurred vision, small pupil and light sensitivity Key Market Competitors: Few of the major competitors currently working in the global anterior uveitis treatment market are Bausch & Lomb Incorporated, Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., EyeGate, Clearside Biomedical, Aldeyra Therapeutics, Aciont Inc., Sirion Therapeutics, Inc., EyePoint Pharmaceuticals, UAB Health System and others Competitive Analysis: Global anterior uveitis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The report includes market shares of anterior uveitis treatment market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa Recent Developments in the Market: In July 2019, Aldeyra Therapeutics, Inc. announced the results from the noninfectious anterior uveitis SOLACE Trial.
Market Analysis and Insights:- Global Anterior Uveitis Treatment MarketGlobal Anterior Uveitis Treatment Market By Treatment (Corticosteroids, Cycloplegic, Anti- TNF Agents, Immunosuppressants), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026Market Analysis: Global Anterior Uveitis Treatment MarketGlobal anterior uveitis treatment market is set to witness a substantial CAGR of 5.55% in the forecast period of 2019- 2026.
Increasing cases of anterior uveitis and rising healthcare expenditure are the factor for the growth of this market.Market Definition: Global Anterior Uveitis Treatment MarketAnterior uveitis is a condition which causes inflammation in the middle layer of the eyes.
Some of the common symptoms of this condition are red & sore eyes, blurred vision, small pupil and light sensitivity.
It usually occurs whenever eyes go through any trauma.Get More Insight About the Global Anterior Uveitis Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-anterior-uveitis-treatment-marketMarket DriversRising aging population will drive the market growthIncreasing cases of the optical infections will also accelerate the market growthGrowing disposable income will also enhance the growth of this marketFavorable government regulations will also contribute as a factor accelerating the growth of this marketMarket RestraintsHigh price of the medication will restrain the market growthLack of knowledge about eye disorders will also hamper the growth of this marketSide effect associated with corticosteroid treatment which can cause Intraocular Pressure elevation which will also restrict the market growthKnow More About this Report @ https://www.databridgemarketresearch.com/reports/global-anterior-uveitis-treatment-marketSegmentation: Global Anterior Uveitis Treatment MarketBy TreatmentCorticosteroidsCycloplegicAnti- TNF AgentsImmunosuppressantsBy Distribution ChannelHospital PharmaciesRetail PharmaciesOnline PharmaciesBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesRest of Asia-PacificSouth AmericaBrazilRest of South AmericaMiddle East and AfricaSouth AfricaRest of Middle East and AfricaKey Developments in the Market:In July 2019, Aldeyra Therapeutics, Inc. announced the results from the noninfectious anterior uveitis SOLACE Trial.
The company also partnered with two finance companies, EW Healthcare Partners and SWK Holdings Corporation, to fund the commercial development of Dexycu and DurasertCompetitive Analysis:Global anterior uveitis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The report includes market shares of anterior uveitis treatment market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Key Market Competitors:Few of the major competitors currently working in the global anterior uveitis treatment market are Bausch & Lomb Incorporated, Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., EyeGate, Clearside Biomedical, Aldeyra Therapeutics, Aciont Inc., Sirion Therapeutics, Inc., EyePoint Pharmaceuticals, UAB Health System and others.Research Methodology: Global Anterior Uveitis Treatment MarketData collection and base year analysis is done using data collection modules with large sample sizes.
Market Analysis and Insights:- Global Anterior Uveitis Treatment MarketGlobal Anterior Uveitis Treatment Market By Treatment (Corticosteroids, Cycloplegic, Anti- TNF Agents, Immunosuppressants), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026Market Analysis: Global Anterior Uveitis Treatment MarketGlobal anterior uveitis treatment market is set to witness a substantial CAGR of 5.55% in the forecast period of 2019- 2026.
Increasing cases of anterior uveitis and rising healthcare expenditure are the factor for the growth of this market.Market Definition: Global Anterior Uveitis Treatment MarketAnterior uveitis is a condition which causes inflammation in the middle layer of the eyes.
Some of the common symptoms of this condition are red & sore eyes, blurred vision, small pupil and light sensitivity.
It usually occurs whenever eyes go through any trauma.Get More Insight About the Global Anterior Uveitis Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-anterior-uveitis-treatment-marketMarket DriversRising aging population will drive the market growthIncreasing cases of the optical infections will also accelerate the market growthGrowing disposable income will also enhance the growth of this marketFavorable government regulations will also contribute as a factor accelerating the growth of this marketMarket RestraintsHigh price of the medication will restrain the market growthLack of knowledge about eye disorders will also hamper the growth of this marketSide effect associated with corticosteroid treatment which can cause Intraocular Pressure elevation which will also restrict the market growthKnow More About this Report @ https://www.databridgemarketresearch.com/reports/global-anterior-uveitis-treatment-marketSegmentation: Global Anterior Uveitis Treatment MarketBy TreatmentCorticosteroidsCycloplegicAnti- TNF AgentsImmunosuppressantsBy Distribution ChannelHospital PharmaciesRetail PharmaciesOnline PharmaciesBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesRest of Asia-PacificSouth AmericaBrazilRest of South AmericaMiddle East and AfricaSouth AfricaRest of Middle East and AfricaKey Developments in the Market:In July 2019, Aldeyra Therapeutics, Inc. announced the results from the noninfectious anterior uveitis SOLACE Trial.
The company also partnered with two finance companies, EW Healthcare Partners and SWK Holdings Corporation, to fund the commercial development of Dexycu and DurasertCompetitive Analysis:Global anterior uveitis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The report includes market shares of anterior uveitis treatment market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Key Market Competitors:Few of the major competitors currently working in the global anterior uveitis treatment market are Bausch & Lomb Incorporated, Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., EyeGate, Clearside Biomedical, Aldeyra Therapeutics, Aciont Inc., Sirion Therapeutics, Inc., EyePoint Pharmaceuticals, UAB Health System and others.Research Methodology: Global Anterior Uveitis Treatment MarketData collection and base year analysis is done using data collection modules with large sample sizes.
